CS
FULC icon

Credit Suisse’s Fulcrum Therapeutics FULC Stock Holding History

Credit Suisse’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-52,062
Closed -$148K – 3197
2023
Q1 		$148K Buy
52,062
+8,242
+19% +$73.8K ﹤0.01% 3169
2022
Q4 		$319K Buy
43,820
+21,230
+94% +$138K ﹤0.01% 3002
2022
Q3 		$183K Buy
22,590
+1,329
+6% +$9.52K ﹤0.01% 3278
2022
Q2 		$104K Buy
21,261
+3,105
+17% +$30.3K ﹤0.01% 3518
2022
Q1 		$429K Sell
18,156
-596
-3% -$8.44K ﹤0.01% 3059
2021
Q4 		$332K Buy
+18,752
New +$371K ﹤0.01% 4079

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's FULC Position: Q2 2023 in Review

Credit Suisse sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 52,062 shares — an estimated $148K sold.

Credit Suisse first reported a position in FULC in Q4 2021 and held it in 6 quarters. The position peaked at $429K in Q1 2022. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Credit Suisse reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 52,062 Fulcrum Therapeutics shares in Q2 2023, an estimated $148K.
  • Credit Suisse first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 6 quarters.
  • Credit Suisse's Fulcrum Therapeutics position peaked at $429K in Q1 2022.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.